These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26669820)

  • 41. Rapid phenotypic assay of antimycobacterial susceptibility pattern by direct mycobacteria growth indicator tube and phage amplified biological assay compared to BACTEC 460 TB.
    El-Sayed Zaki M; Goda T
    Tuberculosis (Edinb); 2007 Mar; 87(2):102-8. PubMed ID: 17035089
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Treatment of extrapulmonary tuberculosis.
    Dutt AK; Stead WW
    Semin Respir Infect; 1989 Sep; 4(3):225-31. PubMed ID: 2688005
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Anti-Mycobacterium tuberculosis activity of antituberculosis drugs and amoxicillin/clavulanate combination.
    Pagliotto AD; Caleffi-Ferracioli KR; Lopes MA; Baldin VP; Leite CQ; Pavan FR; Scodro RB; Siqueira VL; Cardoso RF
    J Microbiol Immunol Infect; 2016 Dec; 49(6):980-983. PubMed ID: 26454420
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A new Multi-PCR-SSCP assay for simultaneous detection of isoniazid and rifampin resistance in Mycobacterium tuberculosis.
    Cheng X; Zhang J; Yang L; Xu X; Liu J; Yu W; Su M; Hao X
    J Microbiol Methods; 2007 Aug; 70(2):301-5. PubMed ID: 17543399
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children.
    Seifart HI; Parkin DP; Donald PR
    Pediatr Infect Dis J; 1991 Nov; 10(11):827-31. PubMed ID: 1749695
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Co-encapsulation of isoniazid and rifampicin in liposomes and characterization of liposomes by derivative spectroscopy.
    Gürsoy A; Kut E; Ozkirimli S
    Int J Pharm; 2004 Mar; 271(1-2):115-23. PubMed ID: 15129978
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Isoniazid induces its own resistance in nonreplicating Mycobacterium tuberculosis.
    Siddiqi S; Takhar P; Baldeviano C; Glover W; Zhang Y
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2100-4. PubMed ID: 17438054
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Antituberculosis drug resistance patterns in adults with tuberculous meningitis: results of haydarpasa-iv study.
    Senbayrak S; Ozkutuk N; Erdem H; Johansen IS; Civljak R; Inal AS; Kayabas U; Kursun E; Elaldi N; Savic B; Simeon S; Yilmaz E; Dulovic O; Ozturk-Engin D; Ceran N; Lakatos B; Sipahi OR; Sunbul M; Yemisen M; Alabay S; Beovic B; Ulu-Kilic A; Cag Y; Catroux M; Inan A; Dragovac G; Deveci O; Tekin R; Gul HC; Sengoz G; Andre K; Harxhi A; Hansmann Y; Oncu S; Kose S; Oncul O; Parlak E; Sener A; Yilmaz G; Savasci U; Vahaboglu H
    Ann Clin Microbiol Antimicrob; 2015 Nov; 14():47. PubMed ID: 26538030
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterization of mutations causing rifampicin and isoniazid resistance of Mycobacterium tuberculosis in Syria.
    Madania A; Habous M; Zarzour H; Ghoury I; Hebbo B
    Pol J Microbiol; 2012; 61(1):23-32. PubMed ID: 22708343
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis by the direct thin-layer agar method.
    Robledo J; Mejia GI; Paniagua L; Martin A; Guzmán A
    Int J Tuberc Lung Dis; 2008 Dec; 12(12):1482-4. PubMed ID: 19017461
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and antimycobacterial activity of isoniazid derivatives from renewable fatty acids.
    Rodrigues MO; Cantos JB; D'Oca CR; Soares KL; Coelho TS; Piovesan LA; Russowsky D; da Silva PA; D'Oca MG
    Bioorg Med Chem; 2013 Nov; 21(22):6910-4. PubMed ID: 24103427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Three-month course of rifampicin and isoniazid for the treatment of latent tuberculous infection].
    Salinas C; Pascual Erquicia S; Diez R; Aguirre U; Egurrola M; Altube L; Capelastegui A
    Med Clin (Barc); 2010 Sep; 135(7):293-9. PubMed ID: 20800162
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rapid speciation of 15 clinically relevant mycobacteria with simultaneous detection of resistance to rifampin, isoniazid, and streptomycin in Mycobacterium tuberculosis complex.
    Shenai S; Rodrigues C; Mehta A
    Int J Infect Dis; 2009 Jan; 13(1):46-58. PubMed ID: 18565777
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Monoammonium glycyrrhizinate protects rifampicin- and isoniazid-induced hepatotoxicity via regulating the expression of transporter Mrp2, Ntcp, and Oatp1a4 in liver.
    Zhou L; Song Y; Zhao J; Qin H; Zhang G; Zhou Y; Wu X
    Pharm Biol; 2016; 54(6):931-7. PubMed ID: 26987268
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vitro bactericidal activity of oxazolidinone, RBx 8700 against Mycobacterium tuberculosis and Mycobacterium avium complex.
    Rao M; Sood R; Malhotra S; Fatma T; Upadhyay DJ; Rattan A
    J Chemother; 2006 Apr; 18(2):144-50. PubMed ID: 16736882
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Isoniazid and rifampicin resistance mutations and their effect on second-line anti-tuberculosis treatment.
    Abate D; Tedla Y; Meressa D; Ameni G
    Int J Tuberc Lung Dis; 2014 Aug; 18(8):946-51. PubMed ID: 25199009
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Encapsulating Rifampicin into SLNs: A Viable Option for Managing its Bioavailability Issues Upon Co-Delivery with Isoniazid.
    Singh H; Sood R; Chaira T; Khanna A; Upadhaya DJ; Bambal R; Bhatnagar PK; Singh M; Kaur IP
    Curr Drug Deliv; 2020; 17(4):343-347. PubMed ID: 32077827
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conjugated and Entrapped HPMA-PLA Nano-Polymeric Micelles Based Dual Delivery of First Line Anti TB Drugs: Improved and Safe Drug Delivery against Sensitive and Resistant Mycobacterium Tuberculosis.
    Upadhyay S; Khan I; Gothwal A; Pachouri PK; Bhaskar N; Gupta UD; Chauhan DS; Gupta U
    Pharm Res; 2017 Sep; 34(9):1944-1955. PubMed ID: 28685299
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Mycobacterium resistance to antimycobacterial reagent.
    Aghandous R; Zouhdi M; Zizi M; Errami M; Idrissi L
    Therapie; 1999; 54(5):623-5. PubMed ID: 10667100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.